8-K: Opus Genetics Secures $25M in Private Placement

Opus Genetics, Inc. announced a $25.0 million private placement of Series B Non-Voting Convertible Preferred Stock to fund its gene therapy clinical programs and general corporate purposes.

Summary

• Opus Genetics, Inc. entered into a Securities Purchase Agreement on February 13, 2026, for a private placement of 7,374,632 shares of its Series B Non-Voting Convertible Preferred Stock.
• The private placement closed on February 18, 2026, at a purchase price of $3.39 per share, raising approximately $25.0 million in aggregate gross proceeds.
• The company expects to use the net proceeds to advance its gene therapy clinical programs, as well as for working capital and general corporate purposes.
• The Series B Preferred Stock is non-voting, except for specific actions that would adversely alter its rights, and is convertible into common stock at a 1:1 ratio.
• Conversion of the Series B Preferred Stock into common stock is subject to stockholder approval of an increase in authorized common shares at the 2026 annual meeting.
• The company reported a preliminary cash balance of $45 million as of December 31, 2025, which would increase to a pro forma cash balance of $70 million after giving effect to the private placement proceeds.
• A Registration Rights Agreement was also entered into, requiring the company to register the resale of common stock issuable upon conversion of the Series B Preferred Stock by April 19, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as the successful private placement provides essential capital for advancing the company's gene therapy pipeline and strengthens its financial position, crucial for a development-stage biotech.

Positives

• Successfully raised approximately $25.0 million in gross proceeds through a private placement, strengthening the company's financial position.
• The capital infusion increases the pro forma cash balance to $70 million as of December 31, 2025, providing significant liquidity.
• Proceeds are earmarked to advance critical gene therapy clinical programs, supporting the company's core strategic objectives.
• Funds will also be used for working capital and general corporate purposes, ensuring operational stability.

Negatives

• Full conversion of the Series B Preferred Stock into common stock is contingent upon obtaining stockholder approval at the 2026 annual meeting, introducing a condition.
• The preliminary cash balance of $45 million as of December 31, 2025, is unaudited and subject to adjustment.

Risks

• The conversion of Series B Preferred Stock into common stock requires stockholder approval to increase authorized common shares, which may not be obtained.
• Beneficial ownership limitations may restrict the ability of certain holders of Series B Preferred Stock to convert their shares immediately, potentially impacting liquidity for those investors.
• Forward-looking statements regarding the use of proceeds and clinical program advancement are subject to known and unknown risks, uncertainties, and assumptions, and actual results may differ materially.
• The company's business is subject to substantial risks and uncertainties, including those identified in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Future Outlook

The company intends to use the net proceeds from the private placement to advance its gene therapy clinical programs, as well as for working capital and general corporate purposes. The company will also seek stockholder approval at its 2026 annual meeting to increase authorized common shares to permit conversion of the Series B Preferred Stock.

Management Comments

• The company intends for forward-looking statements to be covered by safe harbor provisions, acknowledging that actual results may differ materially due to various factors.

Industry Context

StockSavvy.ai notes that securing significant funding is crucial for gene therapy companies, which often have high research and development costs and long development timelines. This capital raise positions Opus Genetics to advance its pipeline in a competitive sector, demonstrating investor confidence in its programs despite the inherent risks of early-stage biotechnology.

Comparison to Industry Standards

• The structure of this private placement, involving non-voting convertible preferred stock with conversion contingent on shareholder approval and including registration rights, is a common financing mechanism for development-stage biotechnology companies. This approach allows companies to raise capital quickly from institutional investors while deferring potential common stock dilution and managing regulatory listing requirements.
• The provision for liquidated damages for delays in registration statement effectiveness is a standard protective clause for investors in such private placements, aligning with practices seen in similar deals for companies like Sarepta Therapeutics or Editas Medicine during their earlier financing rounds, where timely liquidity for investors is critical.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential future dilution upon conversion of Series B Preferred Stock, but also benefit from strengthened financial position and continued funding for clinical programs.
• Series B Preferred Stock Holders: Receive an investment opportunity with protective voting rights for certain adverse changes and registration rights for future liquidity, subject to stockholder approval for conversion.
• Employees: Continued funding for research and development programs, supporting job security and project advancement.
• Customers/Patients: Advancement of gene therapy clinical programs could lead to new treatments.

Next Steps

• Submit to stockholders the approval of an increase to the company's authorized common stock at its 2026 annual meeting.
• Prepare and file an initial registration statement with the SEC by April 19, 2026, to register the resale of common stock issuable upon conversion.
• Use reasonable best efforts to have the registration statement declared effective within 60 days of the earlier of its filing date/Filing Deadline or SEC notification of no review.
• Advance gene therapy clinical programs using the net proceeds from the private placement.

Key Dates

Recommendation

The successful capital raise provides crucial funding for Opus Genetics' gene therapy programs, which is a positive for long-term development. However, the company remains in a clinical development stage, and the preferred stock conversion is subject to shareholder approval, introducing some uncertainty. A 'hold' recommendation is appropriate as the funding secures operations but does not yet provide definitive clinical milestones or market-ready products.

Keywords

Gene therapy, Private placement, Preferred stock, Capital raise, Biotechnology, SEC filing, Clinical programs, Convertible securities, Corporate finance